Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer
Prime Drink Group Announces Convertible Debenture, Board Appointment and Grant of Differed Share Units
Contrasting Athira Pharma (NASDAQ:LONA) & Prime Medicine (NASDAQ:PRME)
Financial Analysis: Prime Medicine (NASDAQ:PRME) & Athira Pharma (NASDAQ:LONA)
Head to Head Review: AgomAb Therapeutics (NASDAQ:AGMB) vs. Prime Medicine (NASDAQ:PRME)
Prime Medicine (NASDAQ:PRME) and Athira Pharma (NASDAQ:LONA) Head to Head Review
Prime Medicine (NASDAQ:PRME) & AgomAb Therapeutics (NASDAQ:AGMB) Critical Survey
Athira Pharma (NASDAQ:LONA) vs. Prime Medicine (NASDAQ:PRME) Financial Analysis
Prime Medicine, Inc. (PRME) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Prime Medicine, Inc. (NYSE:PRME) Receives Consensus Rating of “Moderate Buy” from Analysts
182,133 Shares in Prime Medicine, Inc. $PRME Acquired by DNB Asset Management AS
Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates
Prime Drink Group Announces Management Change
Prime Medicine to Participate in Upcoming Investor Conferences
Athira Pharma (NASDAQ:LONA) & Prime Medicine (NASDAQ:PRME) Financial Review
Prime Medicine, Inc. (NYSE:PRME) Receives Average Recommendation of “Moderate Buy” from Brokerages
Prime Drink Group Secures Exclusive North American Licenses for Beach Day Every Day
Contrasting Eloxx Pharmaceuticals (NASDAQ:ELOX) & Prime Medicine (NYSE:PRME)
Prime Medicine, Inc. (PRME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference
Prime Drink Group Announces First Closing of Private Placement and Grant of Stock Options
Prime: Maintaining 'Buy' On Solidified Catalysts For Wilson's Disease And Beyond
Prime Medicine, Inc. (NYSE:PRME) Given Consensus Rating of “Moderate Buy” by Brokerages
Prime Drink Group Announces Private Placement
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease
Prime Medicine to Present at 8th Annual Evercore Healthcare Conference
Cortexyme (NASDAQ:CRTX) vs. Prime Medicine (NYSE:PRME) Critical Review
Liminatus Pharma (NASDAQ:LIMN) versus Prime Medicine (NASDAQ:PRME) Head to Head Comparison
Analyzing Prime Medicine (NASDAQ:PRME) and Liminatus Pharma (NASDAQ:LIMN)
Prime Medicine, Inc. (PRME) Discusses Liver Disease Franchise Strategy With Focus on Wilson Disease Transcript
Prime Medicine to Present at Jefferies Global Healthcare Conference
CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates
Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer
Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy
Prime Medicine to Participate in Upcoming Investor Conferences
Prime Drink Group Provides Bi-Weekly MCTO Status Report
Prime Medicine, Inc. (PRME) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Prime Drink Group Terminates Rights Offering and Announces Private Placement
Prime Medicine, Inc. (PRME) Presents At Citi's Biopharma Back To School Conference Transcript
Prime Drink Group Provides Bi-Weekly MCTO Status Report
Prime Medicine to Participate in Upcoming Investor Conferences
Prime Drink Group Provides Bi-Weekly MCTO Status Report and Announces Closing of Private Placement
PRME Revenue Misses by 73%
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates
Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates